Quarterly ResultApr 30, 2026, 04:41 PM
EBS Q1 Revenue $156.1M; Net Income $6.8M; Adj. EBITDA $35.6M
AI Summary
Emergent BioSolutions Inc. reported Q1 2026 total revenues of $156.1 million, exceeding the high end of its guidance range, with net income of $6.8 million and adjusted EBITDA of $35.6 million. The company announced a debt refinancing to increase strategic flexibility and reduce interest expense, alongside securing new strategic manufacturing partnerships with Substipharm Biologics and SAB Biotherapeutics. Emergent also maintained market share for NARCAN® Nasal Spray and secured over $200 million in new government contracts for medical countermeasures, while revising its full-year 2026 adjusted net income and adjusted EBITDA forecasts upwards.
Key Highlights
- Q1 2026 Total Revenues $156.1M, down 30% YoY.
- Q1 2026 Net Income $6.8M, down 90% YoY.
- Q1 2026 Adjusted EBITDA $35.6M, down 55% YoY.
- Refinanced term loan with new $150M facility, extending maturity to 2031.
- Secured $140M in Canadian MCM contracts and over $60M in other MCM orders.
- Board authorized up to $50M in share repurchases through March 31, 2027.
- FY 2026 Adjusted Net Income forecast revised to $45M-$65M (from $25M-$45M).
- FY 2026 Adjusted EBITDA forecast revised to $155M-$175M (from $135M-$155M).